Following this Series B round, Geert-Jan Mulder, Managing Partner at Forbion, Florian Muellershausen, Managing Director at Novartis Venture Fund, and a representative of JJDC, will join Citryll’s ...
NEW YORK, NY, USA I 05, 2024 I Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the ...
The BEXMAB study is a multicenter study, taking place in Finland, UK and the U.S., evaluating the safety and efficacy of bexmarilimab, a novel anti-Clever-1 humanized antibody, with standard of care ...
PHILADELPHIA, PA, USA I 09, 2024 I GSK plc (LSE/NYSE: GSK) today announced statistically significant and clinically meaningful overall survival (OS) ...
ATHENS, GA & SAN JOSE, CA, USA I December 09, 2024 I CyanVac LLC, a clinical-stage biotechnology company developing intranasal vaccines using a transformational parainfluenza virus 5 (PIV5)-based ...
In single-ascending dose study in VWD patients, a subcutaneous dose of VGA039 was associated with substantial reductions in bleeds ...
Data demonstrate engineered tRNA from company's first development candidate restores protein production to clinically meaningful levels in two disease ...
BASEL, Switzerland I December 09, 2024 I Cimeio Therapeutics announced today that it has entered a research collaboration with Kyowa Kirin Co., Ltd. (Kyowa Kirin) to develop a novel therapy for ...
CRB-601 is an anti-αvβ8 monoclonal antibody designed to block activation of latent TGFβ in the tumor micro-environment ...
Tiprelestat was safe and well tolerated, with initial signs of clinical efficacy ...
WEST CHESTER, PA, USA I 09, 2024 I Molecular Targeting Technologies, Inc. (MTTI) published preclinical study results for their proprietary ...
When combined with venetoclax and azacitidine (standard-of-care treatments for AML), STX-0712 improved therapeutic efficacy in 60% of patient samples by differential targeting both CCR2-positive ...